NLRP3 and juvenile idiopathic arthritis: In addition, NLRP3 inhibitors have been reported include type 1 interferon (IFN-α and IFN-β), and they are used as a treatment of multiple sclerosis, juvenile idiopathic arthritis, rheumatic diseases, familial Mediterranean fever and other autoimmune diseases caused by mutations in NLRP3 gain of function, but the specific mechanism of their NLRP3 still needs to be studied in depth (Youm et al., 2015a; Malhotra et al., 2015).